BV

BrightView Holdings, Inc. Announces First Quarter Fiscal Year 2024 Earnings Release Date, Conference Call and Webcast

Retrieved on: 
Thursday, January 18, 2024
Construction & Property, Landscape, BV, EST

BrightView Holdings, Inc. (NYSE: BV) will release its earnings results for the first quarter fiscal year 2024 after the market closes on Wednesday, January 31, 2024.

Key Points: 
  • BrightView Holdings, Inc. (NYSE: BV) will release its earnings results for the first quarter fiscal year 2024 after the market closes on Wednesday, January 31, 2024.
  • BrightView will hold a conference call to discuss its results the following morning, Thursday, February 1, 2024, at 8:30 a.m. EST.
  • Instructions to join the conference call are provided below:

Cepheid Receives Expanded FDA Clearance with CLIA Waiver for Xpert® Xpress MVP

Retrieved on: 
Thursday, January 18, 2024
Cepheid variable, MVP, Woman, Yeast, Patient, Vaginitis, Infection, Trichomonas, CLIA, Diagnosis, Bacterial vaginosis, Risk, Recurrence, BV, Medical error, VVC, Candidiasis, PCR, EVP, Physician, Pharmaceutical industry

SUNNYVALE, Calif., Jan. 18, 2024 /PRNewswire/ -- Cepheid announced today that it has received FDA Clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert® Xpress MVP. This multiplex vaginal panel can now be performed in near-patient settings, enabling results within 60 minutes from a single specimen for Bacterial Vaginosis (BV), Vulvovaginal Candidiasis (VVC), and Trichomoniasis (TV). This expanded claim exemplifies Cepheid's commitment to providing expanded access to women's and sexual health by making PCR testing accessible at the point of care. The test runs on Cepheid's GeneXpert Xpress instruments and has been approved for testing women fourteen years of age and older.

Key Points: 
  • SUNNYVALE, Calif., Jan. 18, 2024 /PRNewswire/ -- Cepheid announced today that it has received FDA Clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert® Xpress MVP.
  • This expanded claim exemplifies Cepheid's commitment to providing expanded access to women's and sexual health by making PCR testing accessible at the point of care.
  • The test runs on Cepheid's GeneXpert Xpress instruments and has been approved for testing women fourteen years of age and older.
  • For more information about Cepheid's Xpert Xpress MVP test, please visit Cepheid's website.

Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older

Retrieved on: 
Wednesday, January 10, 2024
Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, CDAD, Development, Woman, Hydrogen chloride, Hypersensitivity, Patient, OGN, Frustration, Thermoregulation, Gynaecology, History, Bacterial vaginosis, Clostridioides, Environment, Recurrence, Research and development, BV, Bacteria, Clindamycin, Lincomycin, Infection, American College

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription to treat bacterial vaginosis (BV).

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription to treat bacterial vaginosis (BV).
  • Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.
  • If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued.
  • Information about XACIATO, and the eVoucher instant savings coupon for eligible patients, can be found at XACIATO.com .

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

Retrieved on: 
Monday, December 11, 2023
Patient, EST, Haematopoietic system, Dor, EFS, MD Anderson Cancer Center, Graft-versus-host disease, Society, Cancer, ASH, HL, CRS, PST, Webcast, Safety, University, BV, Pharmaceutical industry

Affimed will host a webcast following the presentation to review the data and provide a strategic update on acimtamig’s future development.

Key Points: 
  • Affimed will host a webcast following the presentation to review the data and provide a strategic update on acimtamig’s future development.
  • A total of 42 patients were enrolled in the study with 36 patients treated at the RP2D.
  • 32 of the 36 patients treated at the RP2D were HL patients.
  • For the HL patients treated at the RP2D, median EFS was 9.8 months - with 84% patients alive at 12 months.

Torex Gold Reports Results from 2023 Exploration Drilling Program at Media Luna West

Retrieved on: 
Thursday, November 30, 2023
Copper, Architecture, Bureau Veritas, Database, AG, Sulfide, Resource, QA/QC, Granodiorite, Gold, Mesozoic, Metal, News, Quality, Digestion, Technical report, Media Luna, EPO, BV, Skin, Technical

TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Torex Gold Resources Inc. (the “Company” or “Torex”) (TSX: TXG) is pleased to provide results from the 2023 exploration drilling program at Media Luna West. The drilling results support the Company's strategy to further prove up the potential of the Media Luna Cluster and unlock additional near-mine opportunities in order to enhance the future production profile of the Morelos Complex and extend the reserve life beyond 2033.

Key Points: 
  • The Media Luna West target is part of the Media Luna Cluster, hosted within the Mesozoic carbonate-rich Morelos Platform, overlayed by Cuautla and Mezcala formation, and which has been intruded by Paleocene stocks, sills, and dykes of granodioritic to tonalitic composition.
  • The style of mineralization at Media Luna West is characterized by gold with locally high silver and copper grades.
  • Torex has a sampling and analytical Quality Assurance/Quality Control (“QA/QC”) program in place that has been approved by BV and is overseen by Jennifer Betancourt, Chief Exploration Geologist for the Media Luna Project.
  • The program includes 5% each of Certified Reference Materials and Blanks; blind duplicates are not included, but Torex evaluates the results of internal BV laboratory duplicates.

CallTower and BV Investment Partners Join Forces in a Strategic Transaction

Retrieved on: 
Thursday, November 16, 2023
Growth, BV, TMT, Partnership, Financial services, Bank

SALT LAKE CITY, UT and BOSTON, MA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- CallTower , a global leader in cloud-based communications, contact center, and collaboration solutions announced today a strategic investment from BV Investment Partners (BV).

Key Points: 
  • SALT LAKE CITY, UT and BOSTON, MA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- CallTower , a global leader in cloud-based communications, contact center, and collaboration solutions announced today a strategic investment from BV Investment Partners (BV).
  • Q Advisors, a leading global TMT investment bank, acted as exclusive financial advisor to CallTower.
  • BV is investing out of its 11th private equity fund, which closed in September 2023 with $1.75 billion in capital commitments.
  • CallTower’s current major investors and senior management are also investing alongside BV and will continue to provide leadership as CallTower grows.

Suzhou OSAI Biopharma Announces Positive Phase III Clinical Trial Results for Lactobacillus Crispatus Live Bacteria Capsule, Significantly Reducing Recurrence of Gynecological Infections

Retrieved on: 
Tuesday, December 12, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Safety, Piper LBP, Incidence, Vaginitis, Gynaecology, Patient, Infection, Bacterial vaginosis, Medicine in China, MD, Phase, LBP, Obstetrics, Recurrence, BV, Therapure BioPharma Inc, Pharmaceutical industry

Suzhou OSAI Biopharma, Inc., a biopharmaceutical company focused on developing live biotherapeutic products (LBPs), today announced that its Phase III clinical trial of vaginal L. crispatus live bacteria capsule (Lc262-1) has successfully met its primary and secondary endpoints.

Key Points: 
  • Suzhou OSAI Biopharma, Inc., a biopharmaceutical company focused on developing live biotherapeutic products (LBPs), today announced that its Phase III clinical trial of vaginal L. crispatus live bacteria capsule (Lc262-1) has successfully met its primary and secondary endpoints.
  • The Phase III study was a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 320 patients with bacterial vaginosis (BV).
  • After receiving seven days of oral metronidazole and vaginal LBP/placebo combination therapy, the cured patients were followed up for three months.
  • “This Phase III clinical trial is the first registrational Phase III clinical trial globally to evaluate the efficacy of L. crispatus in reducing BV recurrence under a rigorous clinical design.

VINSSEN Co., Ltd. Successfully Supplies Hydrogen Fuel Cell for Industry Project in Singapore

Retrieved on: 
Monday, December 11, 2023
Other Energy, Maritime, Transport, Manufacturing, Alternative Energy, Energy, Other Manufacturing, Hydrogen, Lithium, Classification, Hazard, Lithium-ion battery, HAZID, Shell, Multimedia, FCM, Failure, Roll-on/roll-off, FMECA, BV, ICM, Bureau Veritas

VINSSEN Co., Ltd. (CEO Chil-Han Lee), a company specializing in the production of electric and hydrogen hybrid propulsion systems, has successfully tested and delivered a hydrogen fuel cell system for a trial project involving several key industry partners.

Key Points: 
  • VINSSEN Co., Ltd. (CEO Chil-Han Lee), a company specializing in the production of electric and hydrogen hybrid propulsion systems, has successfully tested and delivered a hydrogen fuel cell system for a trial project involving several key industry partners.
  • VINSSEN signed a contract with Shell in 2022 to supply the hydrogen fuel cell for the project.
  • The main components of the hydrogen fuel cell system delivered by VINSSEN comprise Fuel Cell Module (FCM), Integrated Converter Module (ICM), Lithium-Ion Battery (LIB), and Transformer (TR) for vessel auxiliary power generation.
  • VINSSEN plans to deploy manpower directly to the Singapore shipyard to install, integrate, and inspect the hydrogen fuel cell system.

Spectrum Effect Announces Boulder Ventures Investment and Welcomes Kishen Mangat to the Board of Directors

Retrieved on: 
Tuesday, December 5, 2023
5G, Telecommunications, Software, Networks, Internet, Data Management, Technology, Other Technology, RF, Mobility, Multimedia, General partnership, Kishen Das, Cisco, BV

Spectrum Effect® announced today the Boulder Ventures (BV) investment into Spectrum Effect and the appointment of Kishen Mangat to its Board of Directors.

Key Points: 
  • Spectrum Effect® announced today the Boulder Ventures (BV) investment into Spectrum Effect and the appointment of Kishen Mangat to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20231205476977/en/
    Kishen Mangat is General Partner at Boulder Ventures (BV), where he leads the firm’s enterprise 5G investment strategy.
  • Kishen previously served as the Cisco Systems VP/GM for Mobility and co-founded multiple startups, including BroadHop, Inc.
    "We are appreciative of Boulder Ventures for their endorsement of what we have created and what we are building at Spectrum Effect, and we welcome Kishen Mangat to our Board of Directors," stated Charles Immendorf, Spectrum Effect CEO.
  • "We at Boulder Ventures are impressed with Spectrum Effect’s technologies and solution as well as the set of marquee operator customers," said Kishen Mangat, General Partner at Boulder Ventures.

BV Investment Partners Announces Investment in CallTower

Retrieved on: 
Thursday, November 16, 2023
Cloud, Cisco Webex, TMT, Zoom, Ropes & Gray, Cooley LLP, TEAMS, Software, Growth, Cloud communications, Microsoft, BV

BOSTON, Nov. 16, 2023 /PRNewswire/ -- BV Investment Partners (BV), a middle-market private equity firm focused on the tech-enabled business services, software and IT services sectors, announced today an investment in CallTower, an international leader in delivering cloud-based enterprise-class communications, contact center and collaboration solutions.

Key Points: 
  • BOSTON, Nov. 16, 2023 /PRNewswire/ -- BV Investment Partners (BV), a middle-market private equity firm focused on the tech-enabled business services, software and IT services sectors, announced today an investment in CallTower, an international leader in delivering cloud-based enterprise-class communications, contact center and collaboration solutions.
  • CallTower is based in South Jordan, UT and serves over a million end points covering over 75 countries.
  • Bret England, Chief Executive Officer of CallTower, commented, "The growth of remote and hybrid workforces has driven demand for collaboration platforms and CallTower has been there to help teams stay connected.
  • BV was represented by Ropes & Gray LLP, while CallTower was represented by Cooley LLP, and Q Advisors, a leading global TMT investment bank.